Zeria Pharmaceutical Co., Ltd.
4559・Prime Market・Pharmaceuticals
Governance
The company has adopted the audit & supervisory board structure, comprising 6 directors, 3 of whom are outside directors (outside director ratio of 50%). In addition to a three-tier structure of the Board of Directors, the standing officers' meeting, and the management meeting, the company has established a Compliance Committee and a Sustainability Committee to develop its internal control system. Following the general shareholders' meeting in June 2026, the company plans to transition to a structure of 7 directors, 4 of whom will be outside directors.
Risk Management
The Company has established a compliance department and an internal audit department to prevent risks in advance and to conduct monitoring. Quality and safety risks specific to pharmaceuticals are addressed by the Quality Control Committee, the Safety Evaluation Committee, and the PL Committee, and a system has been built whereby risks with a material impact on management are submitted to the Management Committee, the Board of Full-time Directors, and the Board of Directors. Sustainability risks, including climate change and human capital, are identified and assessed by working groups under the Sustainability Committee and reported to the Board of Directors.
Shareholder Returns
Basic policy is to pay stable and continuous dividends, with payments made twice a year (interim and year-end). Annual dividend for FY2026 (ending March 2026) is ¥49 per share (interim ¥24 + year-end ¥25), an increase of ¥2 year-on-year. For FY2027 (ending March 2027), an annual dividend of ¥50 (interim ¥25 + year-end ¥25) is forecast. A total of 3,000,000 treasury shares were retired during the period.
Dividend Policy
The Company positions returning profits to shareholders as one of its most important management priorities, and its basic policy is to pay stable and continuous dividends. Dividends are paid twice a year, as interim and year-end dividends. For FY2026 (ending March 2026), the annual dividend per share is ¥49 (interim ¥24 + year-end ¥25), an increase of ¥2 year-on-year. The forecast for FY2027 (ending March 2027) is an annual dividend of ¥50 (interim ¥25 + year-end ¥25), an increase of ¥1 year-on-year. The consolidated dividend payout ratio is 25.5%.
ESG
Under the Sustainability Basic Policy formulated in FY2021, the company has identified 10 materiality issues and is addressing climate change response (2050 carbon neutrality target, scenario analysis under 4°C/1.5°C scenarios, FY2025 Scope 1+2 emissions of 12,271 t-CO2) and human capital (female manager ratio of 11.1%, target of 12% or higher by end of FY2028, male childcare leave uptake rate of 50%, certified as a Health & Productivity Management Outstanding Organization 2026, and Kurumin certification obtained).
Last updated: June 25, 2026